RxDoctor Payments Data

Estrella Aguinaldo, MD

Internal Medicine · Carson, CANPI 1548339278

Payments from drug & device makers

$2,972in general payments, 2019–2025

Across 135 payments — averaging $22.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$623
  • AstraZeneca$581
  • Novo Nordisk$340
  • Amgen$260
  • Novartis$227
  • Boehringer Ingelheim$226
  • plus $716 from 17 others

What the payments were for

  • Food & beverage$2,972100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,972 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$77,718
Medicare patients
175
Services billed
685

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin169$164,823
JanuviaSitagliptin Phosphate162$155,329
EliquisApixaban70$51,728
FarxigaDapagliflozin Propanediol49$41,747
OzempicSemaglutide27$23,607
TrulicityDulaglutide14$21,640
RybelsusSemaglutide17$20,941
JanumetSitagliptin Phos/Metformin Hcl15$19,891
XareltoRivaroxaban12$14,071
TradjentaLinagliptin11$13,850
MyrbetriqMirabegron29$6,664
Atorvastatin Calcium543$6,545
Lantus SolostarInsulin Glargine,hum.Rec.Anlog36$5,607
Albuterol Sulfate HfaAlbuterol Sulfate174$5,317
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog15$5,233

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Tradjenta$226$178,673180 claims
Novo NordiskOzempic, Rybelsus$340$44,54944 claims
AstraZenecaFarxiga$581$41,74749 claims
Lilly USA, LLCTrulicity, Humulin N$145$24,44630 claims
Johnson & JohnsonXarelto$623$14,07112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Carson

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →